Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Luc A, Sabourin"'
Publikováno v:
Physiological Reports, Vol 12, Iss 1, Pp n/a-n/a (2024)
Abstract SLK controls the cytoskeleton, cell adhesion, and migration. Podocyte‐specific deletion of SLK in mice leads to podocyte injury as mice age and exacerbates injury in experimental focal segment glomerulosclerosis (FSGS; adriamycin nephrosis
Externí odkaz:
https://doaj.org/article/983993ac9f3844aa8d8698faf39009c1
Autor:
John Abou-Hamad, Jonathan J. Hodgins, Edward Yakubovich, Barbara C. Vanderhyden, Michele Ardolino, Luc A. Sabourin
Publikováno v:
Cells, Vol 13, Iss 1, p 73 (2023)
Targeted therapy resistance frequently develops in melanoma due to intratumor heterogeneity and epigenetic reprogramming. This also typically induces cross-resistance to immunotherapies. Whether this includes additional modes of therapy has not been
Externí odkaz:
https://doaj.org/article/379f6adab2d44074b070f701d04bf5df
Autor:
Cédrik Labrèche, David P. Cook, John Abou-Hamad, Julia Pascoal, Benjamin R. Pryce, Khalid N. Al-Zahrani, Luc A. Sabourin
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-14 (2021)
Abstract Background Breast cancer is a highly heterogeneous disease with multiple drivers and complex regulatory networks. Periostin (Postn) is a matricellular protein involved in a plethora of cancer types and other diseases. Postn has been shown to
Externí odkaz:
https://doaj.org/article/9c9e5ccf6503486ea9f67bb494f2c5be
Autor:
John Abou-Hamad, Jonathan J. Hodgins, Christiano T. de Souza, Brennan Garland, Cédrik Labrèche, Marie Marotel, Cameron Gibson, Samuel Delisle, Julia Pascoal, Rebecca C. Auer, Michele Ardolino, Luc A. Sabourin
Publikováno v:
iScience, Vol 25, Iss 12, Pp 105524- (2022)
Summary: SOX10 is a key regulator of melanoma progression and promotes a melanocytic/differentiated state. Here we identified melanoma cell lines lacking SOX10 expression which retain their in vivo growth capabilities. More importantly, we find that
Externí odkaz:
https://doaj.org/article/627ac5f7b4ef457cb4fd187908d34dd8
Autor:
Khalid N. Al-Zahrani, John Abou-Hamad, Julia Pascoal, Cédrik Labrèche, Brennan Garland, Luc A. Sabourin
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-13 (2021)
Abstract Background Approximately 5–10% of HER2-positive breast cancers can be defined by low expression of the Ste20-like kinase, SLK, and high expression of SOX10. Our lab has observed that genetic deletion of SLK results in the induction of Sox1
Externí odkaz:
https://doaj.org/article/6a9ce1337d9a477fa45fa0766a28d362
Autor:
Khalid N. Al-Zahrani, John Abou-Hamad, Julia Pascoal, Cédrik Labrèche, Brennan Garland, Luc A. Sabourin
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/36d6a3be31bd4ba6b1ecff6a32ff164a
Autor:
Jonathan J. Hodgins, John Abou-Hamad, Ash Hagerman, Edward Yakubovich, Christiano Tanese de Souza, Marie Marotel, Ariel Buchler, Saleh Fadel, Maria M. Park, Claire Fong-McMaster, Mathieu F. Crupi, John C. Bell, Mary-Ellen Harper, Benjamin H. Rotstein, Rebecca C. Auer, Barbara C. Vanderhyden, Luc A. Sabourin, Marie-Claude Bourgeois-Daigneault, David P. Cook, Michele Ardolino
Targeting the PD-1/PD-L1 axis has transformed the field of immune-oncology. While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1a75c947049681a8f0fcf1c901c4543
https://doi.org/10.1101/2022.08.31.506095
https://doi.org/10.1101/2022.08.31.506095
Autor:
Grant A Howe, Bin Xiao, Huijun Zhao, Khalid N Al-Zahrani, Mohamed S Hasim, James Villeneuve, Harmanjatinder S Sekhon, Glenwood D Goss, Luc A Sabourin, Jim Dimitroulakos, Christina L Addison
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TK
Externí odkaz:
https://doaj.org/article/21805c1dece148209f371f94cca74a0d
Autor:
Jonathan J. Hodgins, David P. Cook, Cédrik Labrèche, Benjamin R. Pryce, Michele Ardolino, John Abou-Hamad, Pascale Robineau-Charette, Luc A. Sabourin, Barbara C. Vanderhyden, Khalid N. Al-Zahrani, Rebecca C. Auer, John C. Bell, Christiano Tanese de Souza
Publikováno v:
Oncogene. 39:4592-4602
HER2 is overexpressed in 20–30% of all breast cancers and is associated with an invasive disease and poor clinical outcome. The Ste20-like kinase (SLK) is activated downstream of HER2/Neu and is required for efficient epithelial-to-mesenchymal tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cc4676984bf021acddb906daf74fe3e
https://doi.org/10.1038/s41388-020-1315-3
https://doi.org/10.1038/s41388-020-1315-3
Autor:
Martin R. Jakobsen, Jean-Simon Diallo, Anne Louise Hansen, Taha Azad, Luc A. Sabourin, David Jacobs, Manja Idorn, Geneviève Laroche, Julien van Grevenynghe, Renée M. van der Sluis, Glib Maznyi, Jean Seguin, Fanghui Ren, Daniele Di Carlo, Rozanne Arulanandam, Ragunath Singaravelu, Kathy Fu, David Olagnier, Tommy Alain, Christian K. Holm, Søren R. Paludan, John C. Bell, Marceline Côté, John Hiscott, Demi van der Horst, Naziia Kurmasheva, Lena Cassin, Enrico Palermo, Madalina E. Carter-Timofte, Zaid Taha
Publikováno v:
ACS Infectious Diseases
Carter-Timofte, M E, Arulanandam, R, Kurmasheva, N, Fu, K, Laroche, G, Taha, Z, Van Der Horst, D, Cassin, L, Van Der Sluis, R M, Palermo, E, Di Carlo, D, Jacobs, D, Maznyi, G, Azad, T, Singaravelu, R, Ren, F, Hansen, A L, Idorn, M, Holm, C K, Jakobsen, M R, Van Grevenynghe, J, Hiscott, J, Paludan, S R, Bell, J C, Seguin, J, Sabourin, L A, Côté, M, Diallo, J S, Alain, T & Olagnier, D 2021, ' Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern ', ACS Infectious Diseases, vol. 7, no. 11, pp. 3034-3051 . https://doi.org/10.1021/acsinfecdis.1c00278
Carter-Timofte, M E, Arulanandam, R, Kurmasheva, N, Fu, K, Laroche, G, Taha, Z, Van Der Horst, D, Cassin, L, Van Der Sluis, R M, Palermo, E, Di Carlo, D, Jacobs, D, Maznyi, G, Azad, T, Singaravelu, R, Ren, F, Hansen, A L, Idorn, M, Holm, C K, Jakobsen, M R, Van Grevenynghe, J, Hiscott, J, Paludan, S R, Bell, J C, Seguin, J, Sabourin, L A, Côté, M, Diallo, J S, Alain, T & Olagnier, D 2021, ' Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern ', ACS Infectious Diseases, vol. 7, no. 11, pp. 3034-3051 . https://doi.org/10.1021/acsinfecdis.1c00278
The antimicrobial medication malarone (atovaquone/proguanil) is used as a fixed-dose combination for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travelers. It is an inexpensive, efficacious
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dd3972c1e417035d20e6f69542c6ca0
https://pubmed.ncbi.nlm.nih.gov/34658235
https://pubmed.ncbi.nlm.nih.gov/34658235